The mechanisms of biliary excretion of iron are not well known. The aim of this study was to examine the effect of choleresis induced by several agents on biliary iron excretion in iron-loaded rats. Iron overload was obtained with a diet supplemented by 3% iron carbonyl during a 6-week period. Bile was collected with an external bile fistula. Biliary iron concentration was measured by atomic absorption spectrophotometry, and hepatic iron concentration was measured by a chemical method. Compared with controls, iron overload resulted in a 14-fold increase in hepatic iron concentration but only a 3.9-fold increase in biliary iron output. In iron-loaded rats, taurocholate infusion caused a 1.8-fold significant increase in biliary iron output. Dehydrocholate, given at the same dose, induced a significant but less pronounced (1.3-fold) increase in biliary iron output in spite of a higher bile flow. Taurochenodeoxycholate, tauroursodeoxycholate, and tauro-7-ketolithocholate induced an increase in biliary iron output similar to that observed with taurocholate. The canalicular bile salt-independent choleretic dihydroxydibutyl ether caused a significant but less pronounced increase in biliary iron output (1.4-fold). These results confirm that in iron-loaded rats biliary iron excretion is increased much less than hepatic iron concentration. They show that in iron loaded rats (a) bile salts can increase biliary iron secretion, and (b) this increase is related in part to choleresis and in part to bile salts themselves. This increase may be related to an interaction of iron with bile salt monomers and/or micelles.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/0016-5085(91)90407-c | DOI Listing |
J Gastrointestin Liver Dis
December 2024
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Background And Aims: Wilson disease (WD) results in the defective incorporation of copper into ceruloplasmin as well as decreased biliary copper excretion. Secondary iron overload has also been associated with WD; however, the prevalence is currently unknown. This study aims to determine the prevalence of potential secondary iron overload in patients suspected to have WD.
View Article and Find Full Text PDFBiol Trace Elem Res
December 2024
University of Ibadan, Ibadan, Nigeria.
Manganese (Mn), a trace element, has been documented to exert an important role in the metabolism of cholesterol. Cholesterol gallstone (CG) pathogenesis is directly linked to biliary cholesterol imbalance which could be due to diabetes complications or mismanagement. NF-κβ pathway, an inflammatory regulator, has been implicated in metabolic disease especially in the context of diabetes and gallstone formation.
View Article and Find Full Text PDFAm J Case Rep
December 2024
Department of Gastrointestinal Surgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.
BACKGROUND Open injury of multiple organs in the chest and abdomen, such as the colon, duodenum, kidney, liver and diaphragm, is relatively rare. The rescue of such a patient is difficult, and the results are often unsatisfactory. It is also a challenge for the hospital and doctors.
View Article and Find Full Text PDFJ Am Chem Soc
December 2024
School of Pharmacy, Anhui University of Chinese Medicine, Hefei 230031, China.
BMJ Open
November 2024
Department of Gastroenterology and Hepatology, Yokohama City University School of Medicine Graduate School of Medicine, Yokohama, Kanagawa, Japan
Introduction: Non-alcoholic fatty liver disease, now known as metabolic dysfunction-associated steatotic liver disease (MASLD), is a phenotype of the metabolic syndrome in the liver and is clearly associated with metabolic abnormalities such as hyperglycaemia and dyslipidaemia. Although the prevalence of MASLD is increasing worldwide, there is currently no consensus on the efficacy and safety of the drugs used to treat MASLD/metabolic dysfunction-associated steatohepatitis (MASH). Pemafibrate, a selective peroxisome proliferator-activated receptor alpha modulator, was designed to have higher peroxisome proliferator-activated receptor alfa (PPARα) agonist activity and selectivity than existing PPARα agonists, and in development trials, without increasing creatinine levels, lipid parameters and alanine aminotransferase (ALT) were significantly improved.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!